Khosla Ventures Acquisition Co   (KVSA)
Other Ticker:  
    Sector  Financial    Industry Blank Checks
   Industry Blank Checks
   Sector  Financial
Price: $10.7400 $0.02 0.187%
Day's High: $10.74 Week Perf: 0.19 %
Day's Low: $ 10.73 30 Day Perf: 2.29 %
Volume (M): 6 52 Wk High: $ 11.22
Volume (M$): $ 68 52 Wk Avg: $10.42
Open: $10.74 52 Wk Low: $10.06

 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 5
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Khosla Ventures Acquisition Co
Khosla Ventures Acquisition Co (KVAC) is a special purpose acquisition company (SPAC) sponsored by Khosla Ventures, a prominent venture capital firm. The company was formed with the purpose of merging or acquiring one or more businesses or assets in the technology industry. KVAC raised capital through an initial public offering (IPO) in order to fund its potential acquisitions. The company is led by a team of experienced professionals from Khosla Ventures and aims to leverage their expertise and network in order to identify and acquire promising technology companies. The ultimate goal of Khosla Ventures Acquisition Co is to create long-term value for its shareholders through successful acquisitions and strategic partnerships in the tech sector.

   Company Address: 2128 Sand Hill Road Menlo Park 94025 CA
   Company Phone Number: 376-8500   Stock Exchange / Ticker: NASDAQ KVSA
   KVSA is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Khosla Ventures Acquisition Co

Khosla Ventures Acquisition Co Reveals Promising Financial Performance for Q3 2023 in the Blank Checks Sector

As the fiscal third quarter for 2023 comes to a close, Khosla Ventures Acquisition Co (KVSA) shareholders have been caught off guard by some unexpected but encouraging results. The company's operating loss has shown significant improvement compared to the same period in 2022. Market observers have garnered optimism for the future of KVSA, despite a slightly challenging time frame. Let's examine the financial context and recent stock performance to understand the implications of these results.
Financial Results
During the July to September 2023 earnings cycle, KVSA reported an operating loss of $-0.363495 million. While it may appear concerning to shareholders, it is crucial to note that this marks a considerable improvement from the operating loss of $-0.578988 million in the third quarter of 2022. The reduction in the operating loss is viewed as a positive surprise, even though it falls short of more robust recovery expectations.

Khosla Ventures Acquisition Co

Surge in Expenditures Propels Khosla Ventures Acquisition Co to New Heights in Q2 2023!

In the wake of the second quarter of 2023, insiders in the Major Pharmaceutical Preparations sector have embarked on a detailed examination of Khosla Ventures Acquisition Co's latest financial performance. As of the company's April to June 30, 2023 financial reporting period, the pharmaceutical firm has incurred an operating shortfall of $-0.47521 million. Notably, the absence of any reported top-line figures in this period has left investors speculating on the company's future prospects.
Comparing this year's Q2 performance to the same period in 2022, Khosla Ventures Acquisition Co's operating shortfall has deepened from $-0.39416 million. However, what has truly piqued investors' curiosity is whether the company will soon disclose its top-line results. Remarkably, despite Khosla Ventures Acquisition Co making strides in cultivating revenue streams, the company has failed to exhibit a surplus of $2.098 million in the financial second quarter of 2023, surpassing last year's Q2 performance.

Khosla Ventures Acquisition Co

Khosla Ventures Acquisition Co: Promising Future Outlook Despite Q1 2023 Operating Results Deterioration for Major Pharmaceutical Preparations Company

Khosla Ventures Acquisition Co is a major pharmaceutical company that has caught the attention of investors and market observers alike. The company has been on the rise in recent times, with a series of positive developments and a growing reputation in the industry.
However, some investors were surprised by the lack of anticipated changes at the revenue throughout the January to March 31 2023 reporting season. Despite this, they remain optimistic about the company's future prospects, given the promising operating shortfall figures and improving net income.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com